2022/2819(DEA)
Labelling requirements for unauthorised investigational and unauthorised auxiliary medicinal products for human use
Basic information
2022/2819(DEA)
DEA - Delegated acts procedure
Supplementing 2012/0192(COD)
Subject
4.20.02 Medical research
4.20.02.06 Clinical practice and experiments
4.20.04 Pharmaceutical products and industry
Status
Procedure completed - delegated act enters into force
Key players
-
European Parliament
Committee responsible Rapporteur Appointed
Key events
| Date | Event | Reference | Summary |
|---|---|---|---|
| 06/09/2022 | Non-legislative basic document published | C(2022)06240 | |
| 06/09/2022 | Initial period for examining delegated act 2.0 month(s) | ||
| 14/09/2022 | Committee referral announced in Parliament | ||
| 15/11/2022 | Delegated act not objected by Parliament |
Technical information
| Procedure reference | 2022/2819(DEA) |
|---|---|
| Procedure type | DEA - Delegated acts procedure |
| Procedure subtype | Examination of delegated act |
| Supplementing 2012/0192(COD) | |
| Stage reached in procedure | Procedure completed - delegated act enters into force |
| Committee dossier |
ENVI/9/10019
|
Documentation gateway
-
Document type Reference Date Summary Non-legislative basic document C(2022)06240 06/09/2022